Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Rencofilstat in Healthy Male Subjects

NCT05737433 is registered in ClinicalTrials.gov with Hepion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05737433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05737433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Rencofilstat in Healthy Male Subjects
Lead sponsor
Hepion Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 1, 2023
Completion date
August 4, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nash with fibrosis